Abstract
Glioblastoma is the most common and most aggressive primary brain tumor. Despite maximum treatment, patients only have a median survival time of 15 months, because of the tumor's resistance to current therapeutic approaches. Thus far, methylation of the O 6-methylguanine-DNA methyltransferase (MGMT) promoter has been the only confirmed molecular predictive factor in glioblastoma. Novel "genome-wide" techniques have identified additional important molecular alterations as mutations in isocitrate dehydrogenase 1 (IDH1) and its prognostic importance. This review summarizes findings and techniques of genetic, epigenetic, transcriptional, and proteomic studies of glioblastoma. It provides the clinician with an up-to-date overview of current identified molecular alterations that should ultimately lead to new therapeutic targets and more individualized treatment approaches in glioblastoma.
- Content Type Journal Article
- Category Topic Review
- Pages 1-17
- DOI 10.1007/s11060-011-0793-0
- Authors
- Fonnet E. Bleeker, Department of Neurosurgery, H2 247, Neurosurgical Center Amsterdam, Location AMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
- Remco J. Molenaar, Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
- Sieger Leenstra, Department of Neurosurgery, Erasmus Medical Center, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
- Journal Journal of Neuro-Oncology
- Online ISSN 1573-7373
- Print ISSN 0167-594X
Sent with MobileRSS for iPhone
No comments:
Post a Comment